Outlook Therapeutics
Description
Founded in 2010
Nasdaq listed (ticker: OTLK)
Clinical-stage biopharma company developing an innovative monoclonal antibody for ophthalmic indications
Sector
Biotechnology
Website
Status
Current Portfolio
Year Invested
2017
GMS Ownership
GMS owns a controlling stake in the Company (directly and through JV with Tenshi Lifesciences (“BioLexis”))
Re-positioned company from a biosimilars manufacturer to an innovative drug developer
Re-positioned company from a biosimilars manufacturer to an innovative drug developer